Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• Iovino et al. (2018): High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naive lymphocytes and prevents TTV reactivation  + (Intervention arm: 63 (49-72) Control arm: 58 (47-65))
• Lin et al. (2006): Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study  + (Intervention arm: MW (SD): 50 (11) Placebo arm: MW (SD): 51 (11))
• Arbabi-kalati et al. (2012): Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: A double-blind randomized clinical trial  + (Intervention arm: MW (SD): 51.5 (3.3), Range: 18-70 Placebo arm: MW (SD): 47.2 (3.5), Range: 18-79)
• Raoufinejad et al. (2019): Oral calcitriol in hematopoietic recovery and survival after autologous stem cell transplantation: a randomized clinical trial  + (Intervention arm: mean (SD): 47.53 (13.49), range: 21-65 placebo arm: mean (SD): 46.93 (14.39), range: 18-68)
• Hajimohammadebrahim-Ketabforoush et al. (2019): Effect of Vitamin D Supplementation on Postcraniotomy Pain After Brain Tumor Surgery: A Randomized Clinical Trial  + (Intervention arm: mean (SD): 48.2 (15.3) Control arm: mean (SD): 4.3 (15.2))
• Moslemi et al. (2014): Oral zinc sulphate and prevention of radiation-induced oropharyngealmucositis in patients with head and neck cancers: A double blind, randomized controlled clinical trial  + (Intervention arm: mean (SD): 49.5 (17.47), Range: 18–78 placebo arm: mean (SD): 52.82 (14.03), Range: 22 –71)
• Lin et al. (2009): Effects of zinc supplementation on the survival of patients who received concomitant chemotherapy and radiotherapy for advanced nasopharyngeal carcinoma: follow-up of a double-blind randomized study with subgroup analysis  + (Intervention arm: mean (SD): 49.53 (13.75) Placebo arm: mean (SD): 50.88 (10.01))
• Lin et al. (2008): Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: a double-blinded randomized study  + (Intervention arm: mean (SD): 50 (11) Placebo arm: mean (SD): 51 (11))
• Rastelli et al. (2011): Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial  + (Intervention arm: mean (SD): 60 (8.8) Placebo arm: mean (SD): 63 (7.8))
• Sangthawan et al. (2013): A randomized double-blind, placebo-controlled trial of zinc sulfate supplementation for alleviation of radiation-induced oral mucositis and pharyngitis in head and neck cancer patients  + (Intervention arm: mean (SD): 62 (13) Placebo arm: mean (SD): 60 (12))
• Ribeiro et al. (2017): Effects of zinc supplementation on fatigue and quality of life in patients with colorectal cancer  + (Intervention arm: mean (SD): 62.5 (7.5) Placebo arm: mean (SD): 63.8 (13.3))
• Sangthawan et al. (2015): Effects of zinc sulfate supplementation on cell-mediated immune response in head and neck cancer patients treated with radiation therapy  + (Intervention arm: mean: 62 (43–78) Placebo arm: mean: 60 (29–77))
• Watanabe et al. (2010): Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer  + (Intervention arm: mean: 67.4 (53-78) Control arm: mean: 62.7 (35-86))
• Scher et al. (2011): Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer  + (Intervention arm: mean: 70.4 Control arm: mean: 70.9)
• Jacot et al. (2016): Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study  + (Intervention arm: median (range): 51 (27-74) Control arm: median (range): 49 (25-71))
• Beer et al. (2007): Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators  + (Intervention arm: median (range): 68 (45-87) Placebo arm: median (range): 70 (47-92))
• Attia et al. (2008): Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer  + (Intervention arm: median (range): 72.0 (50.0-85.0) Placebo arm: median (range): 70.0 (52.0-82.0))
• Khan et al. (2017): Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial  + (Intervention arm: median and interquartile ranges of age at diagnosis: 60.5 (55-71) Placebo arm: median and interquartile ranges of age at diagnosis: 62 (54-69))
• Ng et al. (2019): Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial  + (Intervention arm: median=54 (interquartile range: 47-65); placebo arm: median: 56 (interquartile range: 50-64))
• Brown et al. (2019): Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial  + (Intervention arm: median=54 (interquartile range: 47-65); placebo arm: median: 56 (interquartile range: 49-65))
• Braga et al. (2015): Effect of Zinc Supplementation on Serological Response to Vaccination Against Streptococcus Pneumoniae in Patients Undergoing Chemotherapy for Colorectal Cancer  + (MW (SD): 63 (15))
• Hodgson et al. (2012): Reflexology versus Swedish Massage to Reduce Physiologic Stress and Pain and Improve Mood in Nursing Home Residents with Cancer: A Pilot Trial.  + (Mean (Range): 90 years (85-98))
• Liu et al. (2010): Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial  + (Mean (SD) Arm A: 44 (14) Arm B: 42 (14) Arm C: 43 (13) Arm D: 39 (12))
• Cavallini et al. (2005): Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy  + (Mean (SD) Arm Carnitin+ Sildenafil: 63 (3.9) years, Arm Sildenafil: 61 (4.4) years, Arm Placebo: 61.4 (4.4) years)
• Ghoreishi et al. (2007): Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation  + (Mean (SD) = 27 (9.8))

• Azizi et al. (2015): Efficacy of Topical and Systemic Vitamin E in Preventing Chemotherapy-induced Oral Mucositis  + (Mean (SD) = 30.72 (8.41) years)

• Fallahi et al. (2013): Does vitamin E protect salivary glands from I-131 radiation damage in patients with thyroid cancer?  + (Mean (SD) = 31.1 (8.4); range: 17-48 years)
• Upadhyaya et al. (2017): Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differential thyroid cancer: A randomized-controlled trial  + (Mean (SD) = 45.8 (12.1); range: 23-66 years)
• Shamsaei et al. (2017): The Vitamin E Preventive Effect on Taxol-Induced Neuropathy Among Patients With Breast Cancer: A Randomized Clinical Trial  + (Mean (SD) = 47.3 (13.1) years)
• Mondal et al. (2014): Comparative study among glutamine, acetyl-L-carnitine, vitamin-E and methylcobalamine for treatment of paclitaxel-induced peripheral neuropathy  + (Mean (SD) = 54.2 (1.1) years)
• Ferreira et al. (2004): Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: A double-blind randomized trial  + (Mean (SD) = 55.4 (12.5) years)
• Delanian et al. (2003): Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis  + (Mean (SD) = 57 (8) years)
• Salehi et al. (2015): Effect of Vitamin E on Oxaliplatin-induced Peripheral neuropathy Prevention: A Randomized Controlled Trial  + (Mean (SD) = 57.5 (14.0) years)
• Ryan et al. (2013): Curcumin for radiation dermatitis: a randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patients  + (Mean (SD) = 58.1 (2.2) years)
• Villani et al. (2016): Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial  + (Mean (SD) = 59 (6) years)
• Mazdak et al. (2012): Vitamin E reduces superficial bladder cancer recurrence: A randomized controlled Trial  + (Mean (SD) = 59.8 (12.5) years)
• Tsay et al. (2008): Effects of Reflexotherapy on Acute Postoperative Pain and Anxiety Among Patients With Digestive Cancer.  + (Mean (SD) = 59.8 (14.7))
• Stephenson et al. (2000): The Effects of Foot Reflexology on Anxiety and Pain in Patients With Breast and Lung Cancer.  + (Mean (SD) = 68.7 (2.69))
• Johnson et al. (2010): Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain  + (Mean (SD) Age: 60.2 (12.3) years)
• Portenoy et al. (2012): Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial  + (Mean (SD) age = 58 (12.2) years Range = 20-93 years)
• Jatoi et al. (2002): Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study  + (Mean (SD) age per arm: * Megestrol Acetate = 65 (11) years * Dronabinol = 67 (10) years * Megestrol Acetate + Dronabinol = 67 (10) years)
• Lichtmann et al. (2018): Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain  + (Mean (SD) age per arm: Intervention arm = 59.2 (12) years Placebo arm = 60.7 (11.1) years)
• Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies  + (Mean (SD) age per arm: Sativex = 60 (11) years Placebo = 59.6 (11) years)
• Bairati et al. (2005): A Randomized Trial of Antioxidant Vitamins to Prevent Second Primary Cancers in Head and Neck Cancer Patients  + (Mean (SD) in years per arm: - intervention: 62.9 (10.0) - placebo: 62.3 (9.5))
• Bairati et al. (2005): Randomized Trial of Antioxidant Vitamins to Prevent Acute Adverse Effects of Radiation Therapy in Head and Neck Cancer Patients  + (Mean (SD) in years per arm: - intervention: 62.9 (10.0) - placebo: 62.3 (9.5))
• Bairati et al. (2006): Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients  + (Mean (SD) in years per arm: - intervention: 62.9 (10.0) - placebo: 62.3 (9.5))
• Marx et al. (2017): The Effect of a Standardized Ginger Extract on Chemotherapy-Induced Nausea-Related Quality of Life in Patients Undergoing Moderately or Highly Emetogenic Chemotherapy: A Double Blind, Randomized, Placebo Controlled Trial  + (Mean (SD) intervention vs. placebo: 57 (14) vs. 59 (11) years)
• Bossi et al. (2017): A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin  + (Mean (SD) intervention vs. placebo: 58.8 (10.4) vs. 59.5 (10.0) years)
• Jeon et al. (2016): Effect of intravenous high dose Vitamin C on postoperative pain and morphine use after laparoscopic colectomy: A randomized controlled trial  + (Mean (SD) per group: - placebo: 64.5 (10.6) years - intervention: 65.4 (9.6) years)
• Muecke et al. (2013): Impact of treatment planning target volumen (PTV) size on radiation induced diarrhoea following selenium supplementation in gynecologic radiation oncology-a subgroup analysis of a multicenter, phase III trial  + (Mean (SD), range): 64.3 (10.1); 31–80 years)
• Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology  + (Mean (SD), range: 64.3 (10.1), 31–80 years)